Proven engine, fuel already in the tank: a working growth driver plus already-held means to multiply it
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes both (1) a proven, already-producing growth engine that is still small relative to its room, and (2) the means to multiply it are already in the company's hands, connected as one present-tense story. Let's analyze the transcript. The call discusses several products: KEDRAB, the IgG portfolio (CYTOGAM, HEPAGAMB, VARIZIG, WINRHO), and the Inhaled Alpha-1 program (InnovAATe). Also Kamada Plasma. We need to find a specific driver that is already generating real business, and management conveys it has captured only a small part of its potential, and that the company already has the means to scale it up. Look at KEDRAB: They mention increased sales, significant increase in demand, market share expansion. They say the U.S. market is estimated to be $150 million annually. They generated $16 million in revenue in 2022 from KEDRAB. In first half of 2023, significant increase. They expect further momentum. They also mention they extended distribution agreement through 2026. But do they say it's still small relative to its room? They say "significant market share" and "significant increase in demand". They don't explicitly say it's still small relative to the $150 million market. They say they are taking significant market share. But they don't quantify how much they have captured. They say "we are taking significant market share" but not that it's still small. They also mention "we anticipate even further momentum" but that's about growth, not about being small relative to room. They don't say "we have only captured a small fraction" or "early in rollout". They say "significant increase" and "significant market share". So maybe not. Look at the IgG portfolio: They acquired four FDA-approved products. They have a U.S. team established in 2022 promoting them. They say "first time in over a decade that these hyper-immune speciality products have been supported by field-based activity". They are encouraged by positive feedback. They also got FDA approval to manufacture CYTOGAM at their Israeli facility, and Health Canada approval. They expect to initiate sales of product manufactured in Israeli facility in Q4. But is this a growth engine that is already producing? They have sales of these products, but they don't quantify.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| APYX | Apyx Medical Corporation | Q4 2023 | 2024-03-21 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| OUT | Outfront Media Inc. | Q4 2023 | 2024-02-21 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| APAM | Artisan Partners Asset Management Inc. | Q3 2023 | 2023-11-01 | C+ |
| RVLV | Revolve Group, Inc. | Q3 2023 | 2023-11-01 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CPRX | Catalyst Pharmaceuticals, Inc. | Q2 2021 | 2021-08-10 | C+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
NMR · Q1 2024 → YESThe question is whether management describes BOTH a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...YES The transcript shows management describing the Retail business as a growth engine that's already producing real results (net revenue up 22%, income up 133% after reorganization in March, recurring and flow revenue benefits starting to appear) but still small relative to its room (only 1,600 partners deployed out of a much larger potential base, with Q-on-Q progress negative from uncontacted clients, and explicit statements like "if we can broaden our partner base, then we will start to see the benefit" and "we have not been able to contact all clients").
OWL · Q2 2021 → YESThe question is whether management describes BOTH a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...YES The transcript shows management describing Direct Lending as a proven growth engine already producing real activity ($5.1 billion gross deployments in the quarter, $31 billion AUM) while still small relative to its opportunity (explicitly "very small relative to total market opportunity" with a $300 billion market and $1. 5 trillion PE dry powder). They connect this directly to the means already in hand: existing sponsor relationships (500), $8.
WRBY · Q1 2024 → YESThe question is: Does management describe BOTH of a proven, already-producing growth engine that's still small relative to its room, AND the means to multiply it already in the company's hands, as one...